All Releases
|
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program Mar 3, 2010 |
18.0 KB |
|
| |
NEW YORK & SAN FRANCISCO, Mar 03, 2010 (BUSINESS WIRE) -- Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today
announced results from two Phase 3 trials of the investigational
drug dimebon (latrepirdine*) in patients with Alzheimer's disease (AD).
In the CONNECTION trial, dimebon did not meet its co-primary or
...
|
|
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Phase 3 Trial Results for Dimebon in Alzheimer's Disease Mar 2, 2010 |
7.3 KB |
|
| |
SAN FRANCISCO, March 2, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time tomorrow, Wednesday, March 3, to discuss Phase 3 trial results for dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's Disease. A press releas...
|
|
Medivation Announces Participation in Upcoming Conferences Mar 1, 2010 |
7.3 KB |
|
| |
SAN FRANCISCO, March 1, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:
The Cowen Healthcare Conference, Monday, March 8, at 4:45 p.m. Eastern Time at the Marriott Copley Place Hotel in BostonThe ROT...
|
|
Medivation Announces Participation in 12th Annual BIO CEO & Investor Conference Feb 2, 2010 |
7.7 KB |
|
| |
SAN FRANCISCO, Feb 02, 2010 /PRNewswire via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will be a featured speaker on a panel entitled, "Alzheimer's Disease: A Panel To Remember," at the 12th Annual BIO CEO & Investor Conference on Tuesday, February 9, at 9:0...
|
|
Medivation Announces European Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer Jan 12, 2010 |
13.2 KB |
|
| |
SAN FRANCISCO, January 12 /PRNewswire/ -- Medivation, Inc. today announced treatment of the first European patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. The trial, known as AFFIRM, will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who ...
|
|
Medivation Announces Participation in 28th Annual J.P. Morgan Healthcare Conference Jan 4, 2010 |
7.9 KB |
|
| |
SAN FRANCISCO, Jan 04, 2010 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, at 3:30 p.m. Pacific Time at the Westin St. Francis in San Francisco.
Dr...
|
|
Medivation Announces Organizational Changes to Support Anticipated Growth and Future Commercialization Dec 17, 2009 |
10.9 KB |
|
| |
SAN FRANCISCO, Dec 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. today announced changes to its organizational structure to support anticipated growth as the company prepares to transition from a development stage company to a commercial organization. As part of this transition, chief financial officer (CFO) Patrick Ma...
|
|
Medivation to Present at Lazard Capital Markets Sixth Annual Healthcare Conference Nov 11, 2009 |
7.9 KB |
|
| |
SAN FRANCISCO, Nov 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at Lazard Capital Markets Sixth Annual Healthcare conference on Wednesday, November 18, at 8:30 a.m. Eastern Time at the St. Regis Hotel in New York....
|
|
Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update Nov 4, 2009 |
19.0 KB |
|
| |
SAN FRANCISCO, Nov 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN)today reported on its corporate progress and financial results for the third quarter ended September 30, 2009.
"With the signing of our agreement for MDV3100 with Astellas last week, we now have a first-class partner with a global reach, le...
|
|
Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease Nov 3, 2009 |
15.5 KB |
|
| |
NEW YORK & SAN FRANCISCO, Nov 03, 2009 (BUSINESS WIRE) -- Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today
announced the initiation of CONTACT and CONSTELLATION, two Phase 3
trials of the investigational drug dimebon (latrepirdine)* in patients
with moderate-to-severe Alzheimer's disease (AD).
The CONTACT st...
|
|
Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009 Oct 28, 2009 |
8.0 KB |
|
| |
SAN FRANCISCO, Oct 28, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss third quarter 2009 financial results and provide a general business update on Wednesday, November 4, 2009, at 4:30 p.m. Eastern Time. A press release ...
|
|
Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer Oct 27, 2009 |
14.5 KB |
|
| |
TOKYO and SAN FRANCISCO, Oct 27, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Astellas Pharma Inc. ("Astellas") and Medivation, Inc. (Nasdaq: MDVN) announced today that they have entered into a global agreement to develop and commercialize MDV3100, Medivation's investigational drug for the treatment of prostate cancer. MDV3100 is current...
|
|
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100 Oct 26, 2009 |
7.8 KB |
|
| |
SAN FRANCISCO, Oct 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment o...
|
|
Medivation Names Hank Mansbach, M.D., Vice President of Medical Affairs Oct 23, 2009 |
8.3 KB |
|
| |
SAN FRANCISCO, Oct 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the appointment of Hank Mansbach, M.D., as vice president of medical affairs. Dr. Mansbach will lead Medivation's medical affairs activities for dimebon (latrepirdine*), the company's Phase 3 candidate for the treatment of ...
|
|
Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer Sep 23, 2009 |
11.4 KB |
|
| |
SAN FRANCISCO, Sept 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men wit...
|
|
Medivation Announces Participation in Upcoming Conferences Sep 9, 2009 |
7.8 KB |
|
| |
SAN FRANCISCO, Sept 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following conferences:
-- The BioCentury NewsMakers in the Biotech Industry Conference on
Wednesday, September 16, at 11:30 ...
|
|
Medivation Reports Second Quarter 2009 Financial Results and Provides Corporate Update Aug 5, 2009 |
18.4 KB |
|
| |
SAN FRANCISCO, Aug 05, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the second quarter ended June 30, 2009.
"In the past several months, we completed enrollment in our confirmatory, pivotal Phase 3 CONNECTION trial of dimebon (latrepirdine*...
|
|
Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease Jul 30, 2009 |
13.3 KB |
|
| |
NEW YORK & SAN FRANCISCO, Jul 30, 2009 (BUSINESS WIRE) -- Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today
announced the initiation of a Phase 3 trial of the investigational drug
dimebon (latrepirdine)* in patients with Huntington disease. The
international safety and efficacy trial, known as HORIZON, is desi...
|
|
Medivation Announces Second Quarter 2009 Financial Results Teleconference and Webcast on August 5, 2009 Jul 29, 2009 |
7.8 KB |
|
| |
SAN FRANCISCO, July 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2009 financial results and provide a general business update on Wednesday, August 5, 2009, at 4:30 p.m. Eastern Time. A press release ...
|
|
|
A Safety, Tolerability, and Pharmacokinetic Study of Dimebon (Latrepirdine) in Patients with Alzheimer's Disease Already Receiving Donepezil Jul 16, 2009 |
446.6 KB |
|
|
|